These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16041960)

  • 21. [Dialysis and renal transplantation. Update 2012].
    Riegel W; Krüger B; Schnülle P
    Dtsch Med Wochenschr; 2012 Dec; 137(49):2567-70. PubMed ID: 23188637
    [No Abstract]   [Full Text] [Related]  

  • 22. Renal transplantation in children less than six years old.
    Garcia CD; Barros V; Schneider L; Guimarães P; Didone E; Guerra EE; Vitola SP; Garcia VD
    Transplant Proc; 2001; 33(7-8):3595-6. PubMed ID: 11750527
    [No Abstract]   [Full Text] [Related]  

  • 23. Cyclosporin A in patients receiving renal allografts from cadaver donors. 1978.
    Calne RY; Thiru S; McMaster P; Craddock GN; White DJ; Evans DJ; Dunn DC; Pentlow BD; Rolles K
    J Am Soc Nephrol; 1998 Sep; 9(9):1751-6. PubMed ID: 9727384
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach.
    Jürgensen JS; Arns W; Hass B
    Eur J Health Econ; 2010 Feb; 11(1):15-25. PubMed ID: 19296139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contemporary immunosuppression in renal transplant recipients: one size does not fit all.
    Lewis RM; Schnitzler MA
    Transplant Proc; 1999; 31(1-2):254-5. PubMed ID: 10083097
    [No Abstract]   [Full Text] [Related]  

  • 26. The costs and outcomes of kidney transplantation according to initial immunosuppressive drug protocol.
    Manninen DL; Evans RW
    Clin Transpl; 1987; ():269-75. PubMed ID: 3155305
    [No Abstract]   [Full Text] [Related]  

  • 27. Retrospective study on the utilization and cost of immunosuppressive agents among kidney transplant recipients in Taiwan: a 5-year review.
    Lee EK; Tseng PL
    Transplant Proc; 2008 Sep; 40(7):2214-7. PubMed ID: 18790196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful ABO incompatible kidney transplant after an isolated intestinal transplant.
    Cummings LS; Hawksworth JS; Guerra JF; Desai CS; Girlanda R; Matsumoto CS; Fishbein TM; Johnson LB; Melancon JK
    Transplantation; 2011 May; 91(10):e73-4. PubMed ID: 21540718
    [No Abstract]   [Full Text] [Related]  

  • 29. Maintaining immunosuppressive treatment after early allograft nephrectomy does not reduce the risk of anti-HLA allosensitization.
    Del Bello A; Congy-Jolivet N; Kamar N
    Transpl Int; 2015 Sep; 28(9):1113-5. PubMed ID: 25865222
    [No Abstract]   [Full Text] [Related]  

  • 30. Outcome and cost analysis of induction immunosuppression with IL2Mab or ATG in DCD kidney transplants.
    Popat R; Syed A; Puliatti C; Cacciola R
    Transplantation; 2014 Jun; 97(11):1161-5. PubMed ID: 24573113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion to monotherapy maintenance immunosuppression in pediatric renal transplant recipients: a single center experience.
    Sinha R; Tse Y; Marks SD
    Pediatr Transplant; 2011 Feb; 15(1):119-20. PubMed ID: 21155956
    [No Abstract]   [Full Text] [Related]  

  • 32. Trends in the use of immunosuppressive agents by outpatients after renal transplantation at a medical center in southern Taiwan.
    Mao PC; Lee EK; Tseng PL
    Transplant Proc; 2012 Jan; 44(1):185-9. PubMed ID: 22310611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ten-year cost effectiveness of alternative immunosuppression regimens in cadaveric renal transplantation.
    Schnitzler MA; Woodward RS; Lowell JA; Singer GG; Brennan DC
    Transplant Proc; 1999 May; 31(3B Suppl):19S-21S. PubMed ID: 10330963
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical outcome of ABO-incompatible living unrelated donor kidney transplantation.
    Uchida J; Machida Y; Iwai T; Kuwabara N; Iguchi T; Naganuma T; Kumada N; Kawashima H; Nakatani T
    Urol Int; 2011; 86(3):307-14. PubMed ID: 21358172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Penny wise, pound foolish? Coverage limits on immunosuppression after kidney transplantation.
    Gill JS; Tonelli M
    N Engl J Med; 2012 Feb; 366(7):586-9. PubMed ID: 22296029
    [No Abstract]   [Full Text] [Related]  

  • 36. Severe vital depression as the presenting feature of cyclosporin-A-associated thrombotic microangiopathy.
    van der Molen LR; van Son WJ; Tegzess AM; Stegeman CA
    Nephrol Dial Transplant; 1999 Apr; 14(4):998-1000. PubMed ID: 10328490
    [No Abstract]   [Full Text] [Related]  

  • 37. [The first successful combined heart-kidney transplantation in Hungary].
    Benko T; Fehérvári I; Rácz K; Friedrich O; Gálfy I; Török S; Remport A; Járay J; Bodor E; Szabolcs Z
    Orv Hetil; 2008 Jan; 149(4):147-52. PubMed ID: 18201956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mycophenolate mofetil: suggested guidelines for use in kidney transplantation.
    Behrend M
    BioDrugs; 2001; 15(1):37-53. PubMed ID: 11437674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost evaluation of basiliximab treatment for renal transplant patients in Japan.
    Hasegawa T; Imai H; Miki S
    Pharmacoeconomics; 2003; 21(11):791-806. PubMed ID: 12859220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose OKT3 treatment for rejection/induction in kidney and kidney-pancreas transplantation.
    Desai DM; Scandling JD; Knoppel C; Dafoe DC; Alfrey EJ
    Transplant Proc; 1998 Jun; 30(4):1552-4. PubMed ID: 9636630
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.